Oruka Therapeutics (ORKA)

NASDAQ:ORKA

ORKA

Oruka Therapeutics

RESEARCH TOOLSreports

Want to see ORKA full AI Analyst Report?

Oruka Therapeutics (ORKA) Price & Analysis

767 Followers

ORKA Stock Chart & Stats

$67.06

-$0.35(-1.84%)

At close: Jan 08 4:00 PM EST

$67.06

-$0.35(-1.84%)

Day’s Range― - ―

52-Week Range$8.31 - $67.94

Previous CloseN/A

Volume71.58K

Average Volume (3M)530.53K

Market Cap

$3.25B

Enterprise Value$2.41B

Total Cash (Recent Filing)$337.04M

Total Debt (Recent Filing)$1.93M

Price to Earnings (P/E)―

Beta1.06

Next Earnings

May 20, 2026

EPS Estimate

-0.55

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.45

Shares Outstanding49,542,690

10 Day Avg. Volume602,310

30 Day Avg. Volume530,527

Financial Highlights & Ratios

PEG Ratio0.24

Price to Book (P/B)2.93

Price to Sales (P/S)0.00

P/FCF Ratio-15.64

Enterprise Value/Market Cap0.74

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-86.07K

Enterprise Value/Ebitda-21.87

Forecast

1Y Price Target

$80.27

Price Target Upside19.70% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering12

EPS Forecast (FY)-2.36

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Efficacy PotentialTopline results from the Phase 2 EVERLAST-A trial could validate best-in-class efficacy for ORKA-001 in plaque psoriasis and support significant upside if outcomes are strong.

Extended Dosing ConvenienceORKA-002's long half-life and potential for infrequent maintenance dosing could enable at-home administration with fewer injections, improving patient convenience and commercial appeal.

Indication Expansion OpportunityAdvancing ORKA-002 into hidradenitis suppurativa could open a new revenue stream by addressing an additional inflammatory skin condition where similar IL-17 therapies are used.

Bears Say

Clinical Readout DependenceAnalyst's recommendation is contingent on favorable clinical readouts, so lower-than-expected trial efficacy would materially weaken the investment case.

Financing And Market SkepticismLimited cash resources combined with notable short interest indicate financing risk and market skepticism that could pressure the stock if additional funding is required.

Limited Supporting EvidenceKey efficacy claims rely partly on a small, single-center study, which limits confidence until larger, multicenter trials confirm the findings.

Oruka Therapeutics News

Oruka Therapeutics price target raised to $85 from $45 at Wedbush

Wedbush raised the firm’s price target on Oruka Therapeutics (ORKA) to $85 from $45 and keeps an Outperform...

2d ago

ORKA

Leerink sees Spyre’s SPY001 Phase 2 Data as incrementally positive for Oruka

Leerink analyst David Risinger views Spyre Therapeutics’ (SYRE) positive topline results from the open-label SPY001 monotherapy cohort in...

4d ago

ORKA

SYRE

Oruka Therapeutics price target raised to $78 from $73 at BTIG

BTIG analyst Julian Harrison raised the firm’s price target on Oruka Therapeutics (ORKA) to $78 from $73 and...

4d ago

ORKA

Oruka Therapeutics price target raised to $70 from $40 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Oruka Therapeutics (ORKA) to $70 from $40 and keeps a...

4d ago

ORKA

Oruka Therapeutics price target raised to $78 from $50 at Barclays

Barclays raised the firm’s price target on Oruka Therapeutics (ORKA) to $78 from $50 and keeps an Overweight...

10d ago

ORKA

Oruka Therapeutics price target raised to $75 from $50 at UBS

UBS raised the firm’s price target on Oruka Therapeutics (ORKA) to $75 from $50 and keeps a Buy...

11d ago

ORKA

Oruka Therapeutics price target raised to $125 from $60 at Guggenheim

Guggenheim raised the firm’s price target on Oruka Therapeutics (ORKA) to $125 from $60 and keeps a Buy...

11d ago

ABBV

ORKA

Oruka Therapeutics files $1B mixed securities shelf

16:12 EDT Oruka Therapeutics (ORKA) files $1B mixed securities shelf Published first on TheFly – the ultimate source...

15d ago

ORKA

ORKA-001 Phase 1 Completion: What Oruka’s First-in-Human Milestone Means for Investors

Oruka Therapeutics, Inc. ($ORKA) announced an update on their ongoing clinical study. The study, titled “Phase 1, First-in-human,...

16d ago

ORKA

Oruka Therapeutics price target raised to $86 from $58 at Leerink

Leerink raised the firm’s price target on Oruka Therapeutics (ORKA) to $86 from $58 and keeps an Outperform...

1M ago

ORKA

Oruka Therapeutics price target raised to $72 from $47 at Stifel

Stifel raised the firm’s price target on Oruka Therapeutics (ORKA) to $72 from $47 and keeps a Buy...

1M ago

ORKA

Oruka’s ORKA-001 Extension Study Builds Long-Term Case in Psoriasis Market

Oruka Therapeutics, Inc. ($ORKA) announced an update on their ongoing clinical study. Oruka Therapeutics, Inc. is running an...

1M ago

ORKA

Is ORKA a Buy, Before Earnings?

Oruka Therapeutics, Inc. (ORKA) is scheduled to report 4th quarter earnings on 03/05/2026. Regarding Q4 estimates, Wall Street...

1M ago

ORKA

Oruka Therapeutics: Long-Acting IL-17 Platform Drives Upgraded Valuation and Buy Rating

Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on Oruka Therapeutics and increased the price target...

3M ago

ORKA

ORKA FAQ

What was Oruka Therapeutics’s price range in the past 12 months?

Oruka Therapeutics lowest stock price was $8.31 and its highest was $67.94 in the past 12 months.

What is Oruka Therapeutics’s market cap?

Oruka Therapeutics’s market cap is $3.25B.

When is Oruka Therapeutics’s upcoming earnings report date?

Oruka Therapeutics’s upcoming earnings report date is May 20, 2026 which is in 33 days.

How were Oruka Therapeutics’s earnings last quarter?

Oruka Therapeutics released its earnings results on Mar 12, 2026. The company reported -$0.45 earnings per share for the quarter, beating the consensus estimate of -$0.636 by $0.186.

Is Oruka Therapeutics overvalued?

According to Wall Street analysts Oruka Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Oruka Therapeutics pay dividends?

Oruka Therapeutics pays a Notavailable dividend of $19.356 which represents an annual dividend yield of N/A. See more information on Oruka Therapeutics dividends here

What is Oruka Therapeutics’s EPS estimate?

Oruka Therapeutics’s EPS estimate is -0.55.

How many shares outstanding does Oruka Therapeutics have?

Oruka Therapeutics has 49,542,690 shares outstanding.

What happened to Oruka Therapeutics’s price movement after its last earnings report?

Oruka Therapeutics reported an EPS of -$0.45 in its last earnings report, beating expectations of -$0.636. Following the earnings report the stock price went up 25.039%.

Which hedge fund is a major shareholder of Oruka Therapeutics?

Currently, no hedge funds are holding shares in ORKA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Oruka Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-25.30%

Trailing 12-Months

Asset Growth

23.38%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Oruka Therapeutics

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Oruka Therapeutics (ORKA) Earnings & Revenues

Historic Earnings Reports

ORKA Stock 12 Month Forecast

Average Price Target

$80.27

▲(19.70% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","67":"$67","126":"$126","37.5":"$37.5","96.5":"$96.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$125.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":80.27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$80.27</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$45.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,37.5,67,96.5,126],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,50.43,56.16615384615385,61.90230769230769,67.63846153846154,73.37461538461538,79.11076923076922,84.84692307692308,90.58307692307692,96.31923076923076,102.05538461538461,107.79153846153847,113.52769230769229,119.26384615384615,{"y":125,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,50.43,52.72538461538461,55.02076923076923,57.316153846153846,59.61153846153846,61.90692307692308,64.2023076923077,66.4976923076923,68.79307692307692,71.08846153846153,73.38384615384615,75.67923076923077,77.97461538461539,{"y":80.27,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,50.43,50.012307692307694,49.59461538461539,49.176923076923075,48.75923076923077,48.34153846153846,47.923846153846156,47.50615384615384,47.08846153846154,46.67076923076923,46.253076923076925,45.83538461538461,45.417692307692306,{"y":45,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.56,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.09,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.77,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.8,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.6,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.56,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.62,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.17,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.67,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.31,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.3,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.69,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.43,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >